INAB
IN8bio, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
+19/100
Last price
1.39
▼ 0.03 (2.11%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.42
Day high
1.45
Day low
1.37
Volume
45.51K
Market cap
$13.70M
P/E (TTM)
—
52W range
0.88 – 2.73
Trailing performance
Returnvs SPY
1W
+7.34%
+5.4%
1M
+15.83%
+14.7%
3M
+0.72%
-3.8%
6M
-2.80%
-21.0%
YTD
-40.60%
-54.8%
1Y
-41.84%
-58.3%
3Y
-95.54%
-177.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on INAB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
746.97K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 27, 26 | FAIRBAIRN EMILY WANG Director |
STOCK | 724.64K | $0 | Indirect |
| Dec 22, 25 | HO WILLIAM TAI WEI Chief Executive Officer |
STOCK | 36.23K | $50.00K | Direct |
| Dec 22, 25 | MCCALL PATRICK CPA Chief Financial Officer |
STOCK | 7.25K | $10.00K | Direct |
| Dec 22, 25 | ROCHLIN KATE PH.D. Chief Operating Officer |
STOCK | 7.25K | $10.00K | Direct |
| Dec 22, 25 | FAIRBAIRN EMILY WANG Director |
STOCK | 724.64K | $1000.00K | Indirect |
| Dec 22, 25 | BRANDT PETER C Director |
STOCK | 72.46K | $100.00K | Direct |
| Dec 22, 25 | ROEMER ALAN S. Director |
STOCK | 36.23K | $50.00K | Direct |
| Apr 30, 25 | BRANDT PETER C Director |
CONVERSION | 163.93K | $30.23K | Direct |
| Apr 30, 25 | ROEMER ALAN S. Director |
CONVERSION | 113.46K | $20.92K | Direct |
| Apr 30, 25 | MCCALL PATRICK CPA Chief Financial Officer |
CONVERSION | 15.00K | $2.77K | Direct |
| Apr 30, 25 | ROCHLIN KATE PH.D. Chief Operating Officer |
CONVERSION | 12.29K | $2.27K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BRANDT PETER C |
Director | 98.69K | Stock Award(Grant) |
FAIRBAIRN EMILY WANG |
Director | — | Stock Gift |
HO WILLIAM TAI WEI |
Chief Executive Officer | 129.68K | Stock Award(Grant) |
MCCALL PATRICK CPA |
Chief Financial Officer | 9.48K | Stock Award(Grant) |
ROCHLIN KATE PH.D. |
Chief Operating Officer | 9.09K | Stock Award(Grant) |
ROEMER ALAN S. |
Director | 49.51K | Stock Award(Grant) |
Fundamentals
Market cap$13.70M
Enterprise value$-2.08M
Revenue (TTM)—
Gross profit—
EBITDA$-17.80M
Net income$-18.67M
EPS (TTM)$-1.62
Free cash flow$-7.92M
Total cash$17.96M
Total debt$2.18M
Book value / share$1.86
Shares outstanding9.86M
Float7.18M
Short % of float0.72%
Dividend yield0.00%
Beta (5Y)0.30
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.46
PEG ratio—
Price / sales—
Price / book0.75
EV / revenue—
EV / EBITDA0.12
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-111.11%
Return on assets-58.37%
Debt / equity11.86
Current ratio8.21
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $10.21M | $16.96M | $16.83M | $14.06M | -39.8% |
| Selling, general & admin | $9.65M | $12.64M | $13.51M | $14.46M | -23.6% |
| Total operating expense | $19.86M | $29.60M | $30.01M | $28.52M | -32.9% |
| Operating income | -$19.86M | -$29.60M | -$30.01M | -$28.52M | +32.9% |
| Net interest income | $421.00K | $230.00K | $0 | — | +83.0% |
| Pre-tax income | -$19.44M | -$30.44M | -$30.01M | -$28.52M | +36.1% |
| Net income | -$19.44M | -$30.44M | -$30.01M | -$28.52M | +36.1% |
| Net income to common | -$19.44M | -$30.44M | -$30.01M | -$28.52M | +36.1% |
| Basic EPS | -4.44 | -17.05 | -30.00 | -40.80 | +74.0% |
| Diluted EPS | -4.44 | -17.05 | -30.00 | -40.80 | +74.0% |
| EBIT | -$19.86M | -$29.60M | -$30.01M | -$28.52M | +32.9% |
| EBITDA | -$17.36M | -$26.94M | -$27.51M | -$27.42M | +35.6% |
| Basic shares | 4.37M | 1.78M | 995.50K | 698.93K | +145.1% |
| Diluted shares | 4.37M | 1.78M | 995.50K | 698.93K | +145.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $27.09M | $11.12M | $21.28M | $18.18M | — | +143.6% |
| Cash & short-term investments | $27.09M | $11.12M | $21.28M | $18.18M | — | +143.6% |
| Total current assets | $27.88M | $12.58M | $24.63M | $22.23M | — | +121.7% |
| Property, plant & equipment | $4.04M | $7.83M | $8.57M | $10.30M | — | -48.4% |
| Goodwill & intangibles | — | — | — | $126.00K | $0 | — |
| Total assets | $32.28M | $20.94M | $33.71M | $33.04M | — | +54.1% |
| Total current liabilities | $3.16M | $3.08M | $5.39M | $5.82M | — | +2.5% |
| Total debt | $2.78M | $5.03M | $4.89M | $5.87M | — | -44.7% |
| Total liabilities | $4.72M | $6.47M | $8.77M | $10.31M | — | -26.9% |
| Retained earnings | -$141.10M | -$121.66M | -$91.22M | -$61.21M | — | -16.0% |
| Shareholder equity | $27.56M | $14.48M | $24.94M | $22.73M | — | +90.3% |
| Working capital | $24.72M | $9.49M | $19.23M | $16.41M | — | +160.3% |
| Net tangible assets | $27.56M | $14.48M | $24.94M | $22.73M | — | +90.3% |
| Shares issued | 9.77M | 2.42M | 1.44M | 818.17K | — | +304.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$19.44M | -$30.44M | -$30.01M | -$28.52M | — | +36.1% |
| Depreciation & amortisation | $2.50M | $2.65M | $2.50M | $1.10M | — | -5.8% |
| Stock-based compensation | $3.19M | $5.00M | $4.37M | $3.47M | — | -36.2% |
| Change in working capital | $1.04M | -$1.41M | -$204.00K | -$170.00K | — | +173.5% |
| Operating cash flow | -$12.71M | -$24.15M | -$23.34M | -$24.12M | — | +47.4% |
| Capital expenditure | — | -$187.00K | -$600.00K | -$3.71M | -$309.00K | — |
| Investing cash flow | $0 | -$187.00K | -$600.00K | -$3.71M | — | +100.0% |
| Financing cash flow | $28.64M | $14.18M | $27.04M | $8.99M | — | +101.9% |
| Free cash flow | -$12.71M | -$24.34M | -$23.94M | -$27.83M | — | +47.8% |
| End cash position | $27.09M | $11.12M | $21.28M | $18.18M | — | +143.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $2.49M | $2.61M | $2.65M | $2.10M | $2.49M | — | -4.6% |
| Selling, general & admin | $2.44M | $2.65M | $2.38M | $1.86M | $2.71M | — | -8.0% |
| Total operating expense | $4.93M | $5.27M | $5.03M | $3.97M | $5.20M | — | -6.3% |
| Operating income | -$4.93M | -$5.27M | -$5.03M | -$3.97M | -$5.20M | — | +6.3% |
| Net interest income | $154.00K | $176.00K | $91.00K | $113.00K | $107.00K | — | -12.5% |
| Pre-tax income | -$4.78M | -$5.09M | -$4.94M | -$3.85M | -$5.09M | — | +6.1% |
| Net income | -$4.78M | -$5.09M | -$4.94M | -$3.85M | -$5.09M | — | +6.1% |
| Net income to common | -$4.78M | -$5.09M | -$4.94M | -$3.85M | -$5.09M | — | +6.1% |
| Basic EPS | -0.25 | -0.26 | — | -0.85 | -1.24 | -2.10 | +3.8% |
| Diluted EPS | -0.25 | -0.26 | — | -0.85 | -1.24 | -2.10 | +3.8% |
| EBIT | -$4.93M | -$5.27M | -$5.03M | -$3.97M | -$5.20M | — | +6.3% |
| EBITDA | -$4.48M | -$4.77M | -$4.51M | -$3.44M | -$4.42M | — | +6.0% |
| Basic shares | 19.47M | 19.47M | — | 4.54M | 4.12M | 2.78M | -0.0% |
| Diluted shares | 19.47M | 19.47M | — | 4.54M | 4.12M | 2.78M | -0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $17.96M | $21.94M | $27.09M | $10.69M | $13.23M | -18.2% |
| Cash & short-term investments | $17.96M | $21.94M | $27.09M | $10.69M | $13.23M | -18.2% |
| Total current assets | $18.50M | $22.66M | $27.88M | $11.77M | $13.74M | -18.4% |
| Property, plant & equipment | $2.97M | $3.25M | $4.04M | $4.56M | $5.08M | -8.7% |
| Total assets | $21.75M | $26.27M | $32.28M | $16.77M | $19.37M | -17.2% |
| Total current liabilities | $2.25M | $2.16M | $3.16M | $1.70M | $1.95M | +4.4% |
| Total debt | $2.18M | $2.35M | $2.78M | $2.96M | $3.12M | -7.5% |
| Total liabilities | $3.38M | $3.48M | $4.72M | $3.58M | $4.13M | -2.9% |
| Retained earnings | -$150.97M | -$146.19M | -$141.10M | -$136.15M | -$132.30M | -3.3% |
| Shareholder equity | $18.36M | $22.78M | $27.56M | $13.19M | $15.24M | -19.4% |
| Working capital | $16.24M | $20.50M | $24.72M | $10.06M | $11.79M | -20.8% |
| Net tangible assets | $18.36M | $22.78M | $27.56M | $13.19M | $15.24M | -19.4% |
| Shares issued | 9.85M | 9.85M | 9.77M | 4.59M | 4.08M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$4.78M | -$5.09M | -$4.94M | -$3.85M | -$5.09M | +6.1% |
| Depreciation & amortisation | $457.00K | $500.00K | $521.00K | $527.00K | $784.00K | -8.6% |
| Stock-based compensation | $352.00K | $401.00K | $711.00K | $692.00K | $955.00K | -12.2% |
| Change in working capital | $227.00K | -$758.00K | $1.57M | -$889.00K | -$572.00K | +129.9% |
| Operating cash flow | -$3.75M | -$4.95M | -$2.14M | -$3.52M | -$3.93M | +24.3% |
| Capital expenditure | -$233.00K | -$9.00K | — | — | — | -2,488.9% |
| Investing cash flow | -$233.00K | -$9.00K | $0 | $0 | $0 | -2,488.9% |
| Financing cash flow | -$51.00K | -$195.00K | $18.49M | $989.00K | $5.27M | +73.8% |
| Free cash flow | -$3.98M | -$4.96M | -$2.14M | -$3.52M | -$3.93M | +19.7% |
| End cash position | $17.96M | $22.16M | $27.09M | $10.96M | $13.23M | -19.0% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.37 | -0.25 | +33.0% |
| Mar 2026 | -0.69 | -0.26 | +62.3% |
| Dec 2025 | -0.48 | -0.45 | +5.3% |
| Sep 2025 | -1.25 | -0.85 | +31.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.34 | 3 | $0 | 0.0% |
| Next quarter | -0.35 | 3 | $0 | 0.0% |
| Current year | -1.11 | 3 | $0 | 0.0% |
| Next year | -0.95 | 3 | $1.11M | 0.0% |
Analyst targets & ownership
Mean target$7.00
High target$10.00
Low target$5.00
Implied upside403.60%
Analyst count3
ConsensusNONE
Strong buy / Buy1 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders7.58%
Held by institutions38.45%
Institutions holding22
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.30
+7.21% from price
SMA 20
1.19
+17.13% from price
SMA 50
1.13
+22.94% from price
SMA 100
1.29
+7.64% from price
SMA 200
1.54
-9.93% from price
EMA 12
1.29
+7.51% from price
EMA 26
1.22
+13.91% from price
EMA 50
1.21
+15.00% from price
RSI (14)
66.4
Neutral
MACD (12,26,9)
0.07
Hist 0.03
ATR (14)
0.09
6.40% of price
Realised vol 30D
71.2%
Annualised
Bollinger upper
1.46
20, 2σ
Bollinger lower
0.92
20, 2σ
50 / 200 cross
Death
1.13 vs 1.54
Trend bias
Below 200
-9.93%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.48
More volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
71.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-62.9%
Peak to trough
Max drawdown 5Y
-99.6%
Peak to trough
ATR 14
0.09
6.40% of price
Beta (reported)
0.30
5Y monthly, from filing
Short interest
Shares short
63.11K
Prior 139.90K
Change vs prior
-54.9%
Shorts covering
% of float
0.72%
Normal
% of shares out
0.64%
Against total outstanding
Days to cover
1.5
Liquid
Float
7.18M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 14, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 12, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 11, 25 | Jones Trading | UPGRADE | Hold | Buy |
| Nov 26, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 13, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 12, 24 | Jones Trading | DOWNGRADE | Buy | Hold |
| Jun 14, 24 | Jones Trading | MAINTAINED | Buy | Buy |
| Jun 14, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 4, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 13, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 10, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:30
Split dateJun 6, 2025
SEC filings
Offering Registrations
S-8 · 2026-08-07
Periodic Financial Reports
10-Q · 2026-08-06
Offering Registrations
S-3/A · 2026-05-18
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-05-15
Offering Registrations
S-8 POS · 2026-05-07
Proxy Statements
DEFA14A · 2026-03-26
Corporate Changes & Voting Matters
8-K · 2026-03-12
Corporate Changes & Voting Matters
8-K · 2026-02-27
Headlines
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 12h ago
IN8bio to Present at Sidoti Small-Cap Virtual Conference
GlobeNewswire · 15d ago
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 27d ago
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
GlobeNewswire · 28d ago
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 58d ago
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewswire · 62d ago
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
GlobeNewswire · 90d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.